Buparlisib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Buparlisib
Accession Number
DB11666
Type
Small Molecule
Groups
Investigational
Description

Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Structure
Thumb
Synonyms
  • Buparlisib
  • Buparlisibum
External IDs
BKM 120 / BKM-120 / BKM-120NX / NVP-BKM-120 / NVP-BKM120
Product Ingredients
IngredientUNIICASInChI Key
Buparlisib hydrochloride194LK4P5K11312445-63-8DGPLYAXBXJXEID-UHFFFAOYSA-N
Categories
UNII
0ZM2Z182GD
CAS number
944396-07-0
Weight
Average: 410.3935
Monoisotopic: 410.167808561
Chemical Formula
C18H21F3N6O2
InChI Key
CWHUFRVAEUJCEF-UHFFFAOYSA-N
InChI
InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
IUPAC Name
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine
SMILES
NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
16654980
PubChem Substance
347828035
ChemSpider
17588300
BindingDB
50380363
ChEBI
71954
ChEMBL
CHEMBL2017974
HET
SD5
Wikipedia
Phosphoinositide_3-kinase_inhibitor
PDB Entries
3sd5 / 5m7e

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableBreast Cancer1
0CompletedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentBreast Cancer / Ovarian Cancer1
1Active Not RecruitingTreatmentCancer of Nasopharynx / Carcinoma of Larynx / Carcinoma, Squamous Cell of Head and Neck / Early Invasive Cervical Squamous Cell Carcinoma / HPV Positive Oropharyngeal Squamous Cell Carcinoma / Hypopharyngeal Cancer1
1Active Not RecruitingTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Tumors, Solid1
1CompletedNot AvailableAdvanced Pancreatic Adenocarcinoma / Advanced Solid Tumors / Dose Escalation / Gastroesophageal Junction Cancer / Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer / Malignant Neoplasm of Stomach / Metastatic Breast Cancer / Metastatic Colorectal Cancer (MCRC) / Preliminary Efficacy / Recurrent Glioblastoma Multiforme / Safety / Triple Negative Metastatic Breast Cancer1
1CompletedBasic ScienceHepatic Impairment1
1CompletedBasic ScienceImpaired kidney function1
1CompletedOtherAdvanced or Metastatic Breast Cancer1
1CompletedTreatment3rd Line GIST1
1CompletedTreatmentAdvanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Colorectal Cancer (MCRC) / Pancreatic Cancer Metastatic1
1CompletedTreatmentAdvanced Solid Tumors / Selected Solid Tumors1
1CompletedTreatmentAdvanced and Selected Solid Tumors1
1CompletedTreatmentBreast Cancer1
1CompletedTreatmentBreast Cancer / Endometrial Cancer / Malignant Neoplasm of Colon / Ovarian Cancer1
1CompletedTreatmentCastration-Resistant Prostate Cancer (CRPC)1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentGlioblastomas1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentLung Cancers / Tumors, Solid1
1CompletedTreatmentMetastatic Breast Cancer1
1CompletedTreatmentMetastatic or Locally Advanced Solid Tumors1
1CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentPI3K Pathway Inhibition / Pre-menopausal Breast Cancer1
1CompletedTreatmentRecurrent Glioblastoma Multiforme / Recurrent Glioblastoma Multiforme (rGBM)1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAgnogenic Myeloid Metaplasia1
1TerminatedTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lunch Cancer1
1TerminatedTreatmentNon Castrate Metastatic Prostate Cancer1
1TerminatedTreatmentProstate Cancer1
1TerminatedTreatmentSquamous Non-Small Cell Lung Cancer1
1WithdrawnTreatmentAdult Solid Neoplasm / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentEndometrial Cancer / Ovarian Cancer / Recurrent Endometrial Cancer / Recurrent Ovarian Cancer1
1, 2Active Not RecruitingTreatmentGlioblastoma Multiforme (GBM)1
1, 2Active Not RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
1, 2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
1, 2CompletedTreatmentBRAF Mutant Metastatic Melanoma1
1, 2SuspendedTreatmentBreast Cancer1
1, 2TerminatedTreatmentHER2 + Breast Cancer / Metastatic Breast Cancer1
1, 2TerminatedTreatmentC-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM1
2Active Not RecruitingTreatmentBreast Cancer / Metastatic Breast Cancer / Triple Negative Breast Cancer (TNBC) / Tumors Metastatic to Brain1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentMetastatic (Spread to Other Areas of the Body) / Prostate Cancer1
2Active Not RecruitingTreatmentMetastatic Transitional Cell Carcinoma of the Urothelium1
2Active Not RecruitingTreatmentThyroid Cancers1
2Active Not RecruitingTreatmentAdvanced thymic carcinoma1
2CompletedTreatmentAdvanced Endometrial Cancer1
2CompletedTreatmentBreast Cancer4
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma1
2CompletedTreatmentEndometrial Cancer1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentHER2-positive Newly Diagnosed, Primary Breast Cancer / HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab1
2CompletedTreatmentHigh Risk Prostate Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentMalignant Lymphomas / Primary Central Nervous System Lymphoma (PCNSL) / Recurrent/Refractory Secondary Central Nervous System Lymphoma1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Head and Neck / Progressive Disease / Recurrent Disease1
2CompletedTreatmentPI3K Pathway Activated Tumors1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentMalignant Melanoma / Metastases1
2TerminatedTreatmentBasal Cell Carcinoma (BCC) / Basal Cell Carcinoma (BCC) of the Skin / Basal Cell Carcinoma of the Skin / Basal Cell Nevus Syndrome / Nevoid Basal Cell Carcinoma (BCC) Syndrome / Nevoid Basal Cell Carcinoma Syndrome / Recurrent Skin Cancer / Skin Neoplasms1
2TerminatedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1
2Unknown StatusTreatmentHead Neck Cancer Squamous Cell Metastatic / Head Neck Cancer Squamous Cell Recurrent1
2WithdrawnTreatmentAdvanced Prostate Cancer1
2WithdrawnTreatmentBreast Cancer / Cholangiocarcinomas / Colorectal Cancers / Lung Cancers / Tumors, Solid1
2WithdrawnTreatmentEndometrial Cancer1
2WithdrawnTreatmentNeoplasms, Breast1
2WithdrawnTreatmentTreatment for Metastatic or Locally Advanced Cervical Cancer1
2, 3CompletedTreatmentBreast Cancer1
3CompletedTreatmentBreast Cancer1
3TerminatedTreatmentMetastatic Breast Cancer / Metastatic Breast Cancer HR+, HER2-1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.81 mg/mLALOGPS
logP2.44ALOGPS
logP2.56ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)5.94ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area89.63 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity103.58 m3·mol-1ChemAxon
Polarizability39.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyridinylpyrimidines
Alternative Parents
Dialkylarylamines / Aminopyrimidines and derivatives / Aminopyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary amines
show 4 more
Substituents
Pyridinylpyrimidine / Dialkylarylamine / Aminopyridine / Aminopyrimidine / Morpholine / Oxazinane / Pyridine / Imidolactam / Heteroaromatic compound / Dialkyl ether
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aminopyrimidine, ring assembly, morpholines, aminopyridine (CHEBI:71954)

Drug created on October 20, 2016 14:38 / Updated on January 14, 2020 07:28